BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Carnival fever hits Lagos as locals celebrate Afro-Brazilian heritage- From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- Instructions to Adjust Work, Life, and Seeking after a Web based Advertising Degree
- Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
- Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December
- 'Yellowstone' made him a fan favorite. His biggest role isn't the one you see.
- After fleeing past Hezbollah fighting, some Israelis on northern border vow to stay
- A definitive Manual for the Over-Ear Earphones
- Scientists document a death from a meat allergy tied to certain ticks
